Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Prostate cancer (PCa) is a leading cause of cancer-related death in men.
• Differential display code 3 (DD3) is a noncoding gene specifically expressed in PCa.
• Sperm-associated antigen 9 (SPAG9) is highly expressed in PCa and represents a therapeutic target.

Purpose of the Study:

• To construct a novel oncolytic adenovirus, DD3-ZD55-SPAG9, utilizing the DD3 promoter.
• To evaluate the combined therapeutic efficacy of DD3-ZD55-SPAG9 and docetaxel for PCa.
• To investigate the underlying mechanisms of the combined therapy.

Main Methods:

• Construction of the oncolytic adenovirus DD3-ZD55-SPAG9.
• In vitro and in vivo studies to assess anti-tumor efficacy.
• Analysis of tumor cell apoptosis and invasion inhibition.

Main Results:

• DD3-ZD55-SPAG9 significantly enhanced the anti-tumor effects of docetaxel in PCa models.
• The combination therapy demonstrated efficacy both in vitro and in vivo.
• Mechanisms involved increased tumor cell apoptosis and reduced tumor cell invasion.

Conclusions:

• The combination of DD3-ZD55-SPAG9 and docetaxel presents a promising therapeutic strategy for prostate cancer.
• This approach offers enhanced efficacy and potential for improved safety in PCa treatment.